Daily Pharma News - 29 September 2026

Today's pharma news roundup covers major regulatory and drug-approval developments from 29 September 2026, with key stories from India, South India, China, Russia, and the world. From US pharma tariffs with exemptions for Indian drugs to the FDA's approval of the first-ever treatment for MCT8 deficiency, here is everything pharmacy students need to know.

US 100% Pharma Tariffs Begin; India Gets Zero-Tariff Exemptions

The United States has imposed a 100% tariff on patented pharmaceutical imports effective 29 September 2026 - a landmark move for global drug trade. Crucially for Indian pharma, rare-disease drugs, infertility drugs, cell and gene therapies, and antibody-drug conjugates (ADCs) manufactured in India and 19 other jurisdictions are exempt and enter at zero tariff. Generic medicines remain completely untouched by the measure.

This development is highly relevant for Indian pharmacy students and the Indian pharmaceutical industry, which supplies a large share of the world's generics. The exemption structure signals that the US continues to depend on Indian manufacturing for complex therapies, while branded generics - India's core export strength - face no tariff impact at all.

CDSCO Tightens Watch on Narcotic-Containing Pharma Drugs

India's Central Drugs Standard Control Organisation (CDSCO) is stepping up scrutiny of pharmaceutical drugs containing narcotic substances, reviewing its regulatory framework to curb diversion of such preparations. The action follows the June NCORD (Narco Coordination Centre) meeting chaired by Home Minister Amit Shah, and gaps in the framework must be fixed by March 2027.

For pharmacy students studying regulatory affairs and drug law, this is a live case study in how India balances legitimate medical access to controlled substances with the fight against drug diversion. Tighter oversight of narcotic-containing formulations will directly affect prescribing, dispensing, and distribution practices nationwide.

Karnataka FDA Cancels 16 Licences, Suspends Pfizer Depot in Fake-Drug Probe

In a major crackdown on spurious drugs, the Karnataka Food Safety and Drug Administration cancelled 16 drug licences and suspended 8 others after a Bidadi farmhouse bust exposed a spurious-drug racket. Medicines worth Rs 5.05 crore were seized in the operation. Notably, a Pfizer depot was suspended for non-cooperation with the investigation, and Pfizer India responded that patient safety remains its top priority.

This enforcement action underscores why spurious and substandard drugs are a core topic in pharmacy education in India. Students should understand how state FDAs license, inspect, and enforce drug quality - and how even multinational companies face consequences when they fail to cooperate with regulators.

China NMPA Approves Pirtobrutinib Across All CLL/SLL Lines

China's National Medical Products Administration (NMPA) has approved pirtobrutinib (brand name Jaypirca) for both treatment-naive and previously treated chronic lymphocytic leukaemia and small lymphocytic lymphoma (CLL/SLL). Data from the BRUIN trial showed a 93.3% response rate, and the European Medicines Agency's CHMP also recommended EU-wide approval back in June.

Pirtobrutinib is a non-covalent BTK inhibitor - an important new pharmacology for oncology pharmacists to know. Its approval across all treatment lines in China, alongside the positive EU opinion, marks it as a globally important addition to CLL/SLL treatment, and Indian oncology pharmacies should watch for its eventual entry into the Indian market.

Russia Registers First Domestic Quadrivalent Meningitis Vaccine

Russia has registered Mentetra, developed by Petrovax Pharm - the country's first domestically produced quadrivalent meningitis vaccine, covering serogroups A, C, W, and Y, for ages 3 months to 55 years. Local production supports the vaccine's entry into Russia's national immunisation schedule.

This story is a strong example of vaccine self-sufficiency strategy that resonates with India's own vaccine story. Pharmacy students studying immunology and vaccinology should note how domestic manufacturing capacity directly shapes national immunisation programmes.

FDA Approves Emcitate, First Treatment for MCT8 Deficiency

In a milestone for rare-disease medicine, the US FDA approved Emcitate (tiratricol) on 28 September 2026 - the first-ever US treatment for MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. This rare X-linked disorder affects thyroid hormone transport in the brain, with a median life expectancy of about 35 years.

For pharmacology students, MCT8 deficiency is a textbook example of a transporter defect with no treatment - until now. Tiratricol, a thyroid hormone analogue, fills a genuine therapeutic vacuum, and its approval will be cited in pharmacology and clinical pharmacy teaching on orphan drugs and rare diseases for years.

FDA Clears Teva's DEGEVMA, Denosumab Biosimilar to Xgeva

The FDA has approved Teva's DEGEVMA (denosumab-adet), a biosimilar to Amgen's Xgeva (denosumab) across all of the originator's indications. This matches a cross-region regulatory theme: China recently accepted Fosun's HLX14 denosumab biosimilar as well.

Denosumab is a RANKL inhibitor used for bone metastases and osteoporosis - a must-know biologic for pharmacy students. The growing wave of denosumab biosimilars in the US and China signals falling prices and wider access to bone-targeted monoclonal antibody therapy, with Indian biosimilar makers likely to follow.

Conclusion

Today's news shows a pharmaceutical industry in regulatory motion: the US redraws trade rules while carving out space for Indian innovation, Indian regulators tighten control over narcotics and spurious drugs, China and Russia advance drug and vaccine approvals on home soil, and the FDA delivers both a first-in-class rare-disease therapy and a new biosimilar. For pharmacy students, the takeaway is clear - regulatory science, biosimilars, and rare-disease pharmacology are where the field is heading. Staying current with approvals and policy is not optional; it is the difference between a pharmacist who follows the profession and one who leads it.

References

← All daily news